CD34/CD133 Enumeration Kit

CD34/CD133 Enumeration Kit

The intended use of the CD34/CD133 Enumeration Kit, IVD is the determination of the absolute cell number of CD34
+
and CD34
+
/CD133
+
hematopoietic progenitor cells by flow cytometry in various human blood products, such as whole blood, leukapheresis harvest, bone marrow, cord blood, and all fractions of CD34
+
and CD133
+
cells separated using a CliniMACS
®
System for
in vitro
diagnostic applications.
The gating strategy of the CD34/CD133 Enumeration Kit is based on the ISHAGE guidelines for simple and standardized enumeration of CD34
+
cells. By employing anti-CD45-FITC, anti-CD34-APC, and anti-CD133/2-PE the kit allows the identification of CD45
+
leucocytes, of CD34
+
hematopoietic progenitor cells, which are dim for CD45
+
fluorescence and show a low side scatter and of CD34
+
/CD133
+
hematopoietic progenitor cells, which are also CD45
dim
with a low side scatter. Additionally, for each sample a control sample is stained with the CD133 control containing anti-CD45-FITC, anti- CD34-APC, anti-CD133/2-PE and anti-CD133/2 pure antibody to block any CD133 staining. This is required for the proper setting of the relevant gate during analysis.
The kit is suitable for single platform technique, enabling the absolute cell count determination by analysis of commercially available counting particles. The CD34/CD133 Enumeration Kit has been designed for use with flow cytometers able to detect 4-color fluorescence (488 nm argon laser, 635 nm red diode laser) and equipped with appropriate computer hardware and software. Optionally, dead cells can be excluded from the analysis by addition of the DNA stain 7-aminoactinomycin D (7-AAD), which is also included in the kit.

Background information

The CD34 antigen is expressed on human hematopoietic stem and progenitor cells constituting a small subpopulation of bone marrow cells and peripheral blood cells. The antigen is absent on fully differentiated hematopoietic cells. After severe damage, for example, after myeloablative conditioning, the hematopoietic system can be reconstituted by transplantation of allogenic or autologous CD34
+
hematopoietic progenitor cells.
CD133 is expressed on a subset of CD34 bright stem and progenitor cells in human fetal liver, bone marrow, cord blood, and peripheral blood but is not found on mature blood cells. In contrast to the CD34 antigen, CD133 is not expressed by late progenitors, such as pre-B-cells, CFU-E, and CFU-G. CD133 has also been found to be expressed on circulating endothelial progenitor cells and fetal neural stem cells as well as on other tissue-specific stem cells.
CD34
+
and CD34
+
/CD133
+
cells may have various therapeutic uses. CD34- and CD133-enriched stem cell grafts have been employed in autologous and allogenic transplantation both in the haploidentical as well as the HLA-matched setting. CD133
+
stem cells can also be utilized in non-hematological applications, such as regenerative medicine. CD133
+
stem cells have lately come into focus in non-hematological applications especially in ischemic heart diseases.

Technical specifications

  • Antigen: CD34
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates:
Product options: 1

Product information

Size
Order no.
Price

CD34/CD133 Enumeration Kit

  • CE–IVD
for 50
tests
(1)
170-070-709
EUR 894,00 

Related products

4 products available